{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:52:51Z","timestamp":1793641971115,"version":"4.5.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.002","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T15:49:16Z","timestamp":1703605756000},"page":"337-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Monoclonal Antibodies in the Treatment of Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Niels W.C.J.","family":"van de Donk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2023.12.002_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-021-00415-5","article-title":"First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018","volume":"11","author":"Brink","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.002_bib4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.hoc.2023.12.002_bib5","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.002_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-Parameter Mass Cytometry Evaluation of Relapsed\/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry Part A : The Journal of the International Society for Analytical Cytology"},{"issue":"15","key":"10.1016\/j.hoc.2023.12.002_bib10","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.002_bib11","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.002_bib12","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","article-title":"Comparison of CD38 antibodies in\u00a0vitro and ex\u00a0vivo mechanisms of action in multiple myeloma","volume":"106","author":"Kinder","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.002_bib14","first-page":"253","article-title":"Lenalidomide for the treatment of relapsed and refractory multiple myeloma","volume":"4","author":"van de Donk","year":"2012","journal-title":"Cancer Manag Res"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.002_bib15","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.002_bib16","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"van der Veer","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.002_bib17","first-page":"288","article-title":"Preclinical chracterization of SAR650984, a humanized anti-CD38 antibody for the treatment of multiple myeloma","author":"Cai","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.002_bib18","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.002_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.002_bib20","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed\/Refractory Multiple Myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"Hemasphere"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.002_bib21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood advances"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib22","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.002_bib23","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10218","key":"10.1016\/j.hoc.2023.12.002_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.002_bib26","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10192","key":"10.1016\/j.hoc.2023.12.002_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.002_bib28","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1182\/blood-2022-162339","article-title":"Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.002_bib29","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1182\/blood-2022-163494","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study","volume":"140","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.002_bib30","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib31","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.002_bib32","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10027","key":"10.1016\/j.hoc.2023.12.002_bib33","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.002_bib34","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood.2020008209","article-title":"Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Dimopoulos","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.002_bib35","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib36","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"issue":"6 Pt 2","key":"10.1016\/j.hoc.2023.12.002_bib37","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/cclm-2015-0888","article-title":"Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)","volume":"54","author":"van de Donk","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10214","key":"10.1016\/j.hoc.2023.12.002_bib40","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.002_bib41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.002_bib43","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.002_bib44","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib45","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.002_bib46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.002_bib47","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.002_bib48","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A\u00a0simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.002_bib50","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study","volume":"39","author":"Stege","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/hematology.2020000161","article-title":"Should all newly diagnosed MM patients receive CD38 antibody-based treatment?","volume":"2020","author":"Korst","year":"2020","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"10.1016\/j.hoc.2023.12.002_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142913","volume":"136","author":"Krishnan","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.002_bib53","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib54","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.002_bib55","doi-asserted-by":"crossref","first-page":"e063037","DOI":"10.1136\/bmjopen-2022-063037","article-title":"Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II\/III randomised controlled trial","volume":"12","author":"Royle","year":"2022","journal-title":"BMJ Open"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.002_bib56","first-page":"1986","article-title":"Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma","volume":"122","author":"Plesner","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.002_bib57","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A\u00a0phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2023.12.002_bib58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.002_bib59","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib60","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib61","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib63","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib64","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib65","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10245","key":"10.1016\/j.hoc.2023.12.002_bib66","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2023.12.002_bib68","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Advances"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.002_bib69","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.002_bib70","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.002_bib71","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(17)30613-7","article-title":"Carfilzomib versus bortezomib: no longer an ENDEAVOR","volume":"18","author":"van de Donk","year":"2017","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2023.12.002_bib72","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.15716","article-title":"Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and\/or pomalidomide refractory multiple myeloma","volume":"186","author":"Hussain","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjh.13776","article-title":"Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach","volume":"174","author":"Alici","year":"2016","journal-title":"Br J Haematol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.12.002_bib75","doi-asserted-by":"crossref","first-page":"TPS8553","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8553","article-title":"Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX)","volume":"38","author":"Bahlis","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.002_bib76","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.002_bib77","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Therapeut"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.002_bib78","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.002_bib79","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10428194.2019.1688324","article-title":"Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma","volume":"61","author":"Hoylman","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2023.12.002_bib81","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1182\/blood-2018-99-115663","article-title":"Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens","volume":"132","author":"Becnel","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib82","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.12.002_bib83","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2021-147323","article-title":"Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.002_bib84","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.002_bib85","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2023.41.16_suppl.8000","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study","volume":"41","author":"Knop","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib86","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A\u00a0phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2023.12.002_bib87","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.002_bib88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.hoc.2023.12.002_bib89","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib90","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.002_bib91","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.002_bib92","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib93","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib94","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.002_bib95","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.002_bib96","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.002_bib97","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jha2.729","article-title":"T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions","volume":"4","author":"O'Neill","year":"2023","journal-title":"EJHaem"},{"issue":"10396","key":"10.1016\/j.hoc.2023.12.002_bib98","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.002_bib99","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.hoc.2023.12.002_bib100","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2021-146047","article-title":"SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed\/Refractory Multiple Myeloma (SGNBCMA-001)","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.002_bib101","doi-asserted-by":"crossref","first-page":"10160","DOI":"10.1182\/blood-2022-157347","article-title":"Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)","volume":"140","author":"Hoffman","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.002_bib102","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.002_bib103","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2022-157945","volume":"140","author":"Richardson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.002_bib104","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2019-124298","article-title":"Preclinical, Translational, and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)","volume":"134","author":"Lonial","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.002_bib105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137743","article-title":"First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"van de Donk","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.002_bib106","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.002_bib107","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical Activity of JNJ-7957, a Novel BCMA\u00d7CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib108","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Advances"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.002_bib109","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A\u00a0novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.002_bib110","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal)\u00a0+ daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.002_bib111","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.002_bib112","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/bloodadvances.2021005220","article-title":"Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed\/refractory multiple myeloma","volume":"5","author":"Frerichs","year":"2021","journal-title":"Blood Advances"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.002_bib113","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.2021012448","article-title":"SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma","volume":"139","author":"Kassem","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.002_bib114","doi-asserted-by":"crossref","first-page":"104663","DOI":"10.1016\/j.ebiom.2023.104663","article-title":"Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity","volume":"93","author":"Hiemstra","year":"2023","journal-title":"EBioMedicine"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.002_bib115","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1182\/blood-2022-159116","article-title":"Preliminary Dose-Escalation Results from a Phase 1\/2 Study of GEN3014 (HexaBody\u00ae-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Spencer","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.002_bib116","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"10292","key":"10.1016\/j.hoc.2023.12.002_bib117","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:19:13Z","timestamp":1760591953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001697"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Antibodies in the Treatment of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}